Indefinite Delivery Contract SPE2DX22D0120

The Indefinite Delivery Contract (IDC) SPE2DX is a single award contract valued at $9,999,999,999.00 held by AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, awarded by the Defense Logistics Agency (DLA) Medical Directorate, supports the Defense Health Agency's TRICARE Pharmacy Program by providing replenishment pharmaceutical and related medical products to multiple TRICARE pharmacy ordering facilities, including the TRICARE Mail Order Pharmacy and TRICARE Specialty Pharmacy Network. Additionally, the contract provides readiness support and backup to the existing CONUS Pharmaceutical Prime Vendor contracts. The contract term runs through December 31, 2031, and encompasses a wide range of critical medical commodities such as specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. This comprehensive prime IDV serves as a global pharmaceutical support vehicle, enabling AmerisourceBergen Drug Corp to supply the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with essential medical products and supplies.

The IDC was competitively awarded following a Special Notice published by the DLA Medical Directorate seeking industry feedback on a draft Statement of Work for the upcoming National Prime Vendor Generation IV contract solicitation. The National Prime Vendor contract will support the TRICARE Pharmacy Program, with pricing based on Federal Supply Schedule, DAPA, or regional DAPA prices plus the contractor's distribution fee and Cost Recovery Rate. The contract term is one base period and one option period not exceeding five years total, and will service a maximum of 12 pharmacy ordering facilities.